It’s time to rethink peer review policies—and consider an “Earth Shot Program”

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

At a recent NIH study section that I chaired, we had many applications that we reviewed as a group before the meeting. At the meeting, we were required to discuss over 50% of the grants.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Wafik S. El-Deiry, MD, PhD, FACP
Director, Joint Program in Cancer Biology, Brown University and Lifespan Cancer Institute
Associate Dean, Oncologic Sciences, Warren Alpert Medical School, Brown University
American Cancer Society Research Professor

YOU MAY BE INTERESTED IN

George F. Tidmarsh has resigned from his job as director of the FDA Center for Drug Evaluation and Research in the aftermath of a lawsuit by a former associate and a probe into what an HHS spokesperson described as “serious concerns about his personal conduct.”
Research has shown that delivering tumor profiling results to cancer patients prior to initiation of treatment and connecting patients harboring an actionable oncogenic mutation with the right targeted therapy can deliver superior patient outcomes. To fulfill this promise of precision medicine, we need to ensure more targeted therapies are available to patients who need them. Fortunately, this work is well underway. xxx:more
Wafik S. El-Deiry, MD, PhD, FACP
Director, Joint Program in Cancer Biology, Brown University and Lifespan Cancer Institute
Associate Dean, Oncologic Sciences, Warren Alpert Medical School, Brown University
American Cancer Society Research Professor

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login